Liraglutide was also shown to mitigate fibrosis in mice through the downregulation of NF-kB signaling and the decrease in levels of TGF-β1, a key regulator of fibrosis in cancer-related lymphedema (Gou et al., 2014; Baik et al., 2022; Kataru et al., 2019). Here, NFKB1 is linked to cancer.